Canary Cure’s CCT-217 demonstrates fat loss and lean body mass preservation in preclinical studies
Canary Cure Therapeutics (Canary Global Inc.) has released preclinical results for its lead candidate, CCT-217, an siRNA therapeutic targeting cannabinoid CB1 receptor (CB1R) and zinc finger protein ...
Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation, and Promises Superior Adherence NEW YORK, Jan. 10, 2025 /CNW/ - Canary Cure Therapeutics ...
Novel siRNA Therapeutic Demonstrates Significant Fat Loss and Remarkable Lean Body Mass Preservation ... obesity treatment," said Raj Reddy, CEO of Canary Cure. "While current therapies often ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback